Tempus AI (NASDAQ:TEM) Trading Up 2.6% – Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM) shares shot up 2.6% on Wednesday . The stock traded as high as $52.00 and last traded at $48.88. 13,657,104 shares traded hands during trading, an increase of 97% from the average session volume of 6,929,281 shares. The stock had previously closed at $47.64.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TEM. Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the company from $45.00 to $65.00 in a report on Monday, November 11th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Bank of America boosted their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Tempus AI Price Performance

The business has a 50 day moving average of $44.77 and a two-hundred day moving average of $47.39. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Buying and Selling

In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the sale, the chief operating officer now owns 982,442 shares of the company’s stock, valued at $38,914,527.62. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of Tempus AI stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the sale, the insider now directly owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,300,761 shares of company stock valued at $51,271,197 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently made changes to their positions in TEM. Exchange Traded Concepts LLC grew its holdings in shares of Tempus AI by 37.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 84,174 shares of the company’s stock worth $2,842,000 after buying an additional 23,070 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Tempus AI during the 4th quarter valued at approximately $372,000. Dakota Wealth Management lifted its holdings in Tempus AI by 189.7% during the 4th quarter. Dakota Wealth Management now owns 60,668 shares of the company’s stock worth $2,048,000 after buying an additional 39,724 shares during the last quarter. Avanza Fonder AB acquired a new position in Tempus AI in the fourth quarter valued at approximately $1,197,000. Finally, Bouvel Investment Partners LLC acquired a new position in shares of Tempus AI during the fourth quarter worth approximately $1,029,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.